ClinicalTrials.gg

Program

arumakimig

Also written as “MAS825” and “Arumakimig”.

In Novartis's pipeline, IL18 Inhibitor, IL1B. Its studies are mostly in Arthritis, Juvenile · Arthritis · Hidradenitis Suppurativa · Enterocolitis · Coronary Disease, led by Novartis.

Furthest: phase 2, since Jan 31, 20197 company-led studies, 3 open or runningNext primary completion: Apr 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis73 open or runningphase 2since Jan 31, 2019Jan 31, 2019Apr 22, 2027phase 2 · NCT07203001
  • Named in Novartis’s own pipeline as MAS825 (arumakimig), phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2019First study: phase 2 study in Hidradenitis SuppurativaFirst studyNCT03827798 · 248 enrolled · United States, Austria, Belgium and more
  2. May 8, 2020Phase 2 study in Respiratory InsufficiencyNCT04382651 · 140 enrolled · United States
  3. Nov 20, 2020Phase 2 study in Lymphoproliferative Syndrome, X-Linked, 2NCT04641442 · 17 enrolled · United States, Czechia, France and more
  4. Nov 30, 2020Phase 1 study in Healthy VolunteersNCT04665154 · 80 enrolled · United States, United Kingdom
  5. Oct 18, 2023Phase 2 study in Coronary DiseaseNCT06097663 · 31 enrolled · United States, Canada, Germany
  6. Sep 9, 2025Phase 2 study in Arthritis, JuvenileNCT07203001 · 30 planned · United States, Canada, France and more
  7. Jul 31, 2026Phase 2 study in VEXAS syndromeNCT07748624 · 120 planned · Japan

Ahead

  1. Apr 22, 2027Primary completion: phase 2 study in Arthritis, JuvenileNCT07203001
  2. Dec 26, 2028Primary completion: phase 2 study in VEXAS syndromeNCT07748624

TargetBeta

“IL18 Inhibitor, IL1B”the company's pipeline, read by Claude · source

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07748624VEXAS syndrome · Japan2RecruitingDec 26, 2028120
NCT07203001Arthritis, Juvenile · United States, Canada, France and more2RecruitingApr 22, 202730
NCT06097663Coronary Disease · United States, Canada, Germany2CompletedOct 27, 202431
NCT04665154Healthy Volunteers · United States, United Kingdom1CompletedAug 3, 202280
NCT04641442Lymphoproliferative Syndrome, X-Linked, 2 · United States, Czechia, France and more2Active, not recruitingOct 14, 202517
NCT04382651Respiratory Insufficiency · United States2CompletedJan 6, 2021140
NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more2CompletedDec 4, 2024248

How it is read

Names in the registry

  • “MAS825”, 6 entries
  • “Arumakimig”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.